<p> UK NEQAS for H&I – SCHEME 6 – HLA ANTIBODY DETECTION ***Results must be submitted by the result deadline which can be found on the UK NEQAS for H&I website***</p><p>Before submitting these results, please ensure that you’re using the latest version of this form and that your laboratory has completed the Scheme 6 Methodology Questionnaire which can be downloaded from our website. The methodology questionnaire must be completed with the first submission of samples each year and after any changes to testing methodology. </p><p>Lab Number: Lab Name: (please complete) Sample identification: </p><p>Date samples received (DD/MM/YYYY): Date samples tested (DD/MM/YYYY): </p><p>IgG RESULTS FOR ASSESSMENT </p><p>Indicate if HLA IgG Class I / Class II antibodies are present for each sample and mark the detection method(s) X X E E</p><p>HLA IgG CI A HLA IgG CII A C C M M N N S S I I I I D D antibody present C antibody present C L L M M C F C F E E U (Positive/Negative/NT) (Positive/Negative/NT) U Sample ID L L</p><p>Please email the completed report by the deadline to:[email protected] NEQ 57, Issue 5 Page 1 of 4 Effective Date 15/02/17 Ref. SOP: 133/NEQ UK NEQAS for H&I – SCHEME 6 – HLA ANTIBODY DETECTION</p><p>Lab Number: Lab Name: </p><p>Sample identification: </p><p>Please complete the following IgG testing information:</p><p>Please mark the methods used to test these samples: Please indicate if the samples have been treated: CDC Luminex Single Antigen No treatment Dilution ELISA Luminex Mixed/Multi Heat Inactivation EDTA Flow cytometry Adsorb Out/SeraClean Beads Other (please specify): Other (please specify): </p><p>Does this apply to all samples?: Yes No Does this apply to all samples?: Yes No</p><p>If no, please provide further details & Sample IDs: If no, please provide further details & Sample IDs: </p><p>Please list any samples that gave ‘high background’ in the Luminex assay(s): </p><p>Please give further details (e.g. was the high background removed by Adsorb Out treatment etc.) </p><p>Comments</p><p>Please email the completed report by the deadline to:[email protected] NEQ 57, Issue 5 Page 2 of 4 Effective Date 15/02/17 Ref. SOP: 133/NEQ UK NEQAS for H&I – SCHEME 6 – HLA ANTIBODY DETECTION</p><p>Lab Number: Lab Name: </p><p>Sample identification: IgM RESULTS (Not assessed)</p><p>Indicate if HLA IgM Class I / Class II antibodies are present for each sample and mark the detection method(s) X X E E</p><p>HLA IgM CI A HLA IgM CII A C C M M N N S S I I I I D D antibody present C antibody present C L L M M C F C F E E U (Positive/Negative/NT) (Positive/Negative/NT) U Sample ID L L</p><p>Please mark the methods used to test these samples: Please indicate if the samples have been treated: CDC Luminex Single Antigen No treatment Dilution ELISA Luminex Mixed/Multi Heat Inactivation EDTA Flow cytometry Adsorb Out/SeraClean Beads Other (please specify): Other (please specify): Does this apply to all samples?: Yes No Does this apply to all samples?: Yes No If no, please provide further details & Sample IDs: If no, please provide further details & Sample IDs: </p><p>Please list any samples that gave ‘high background’ in the Luminex assay(s): </p><p>Please give further details (e.g. was the high background removed by Adsorb Out treatment etc.) </p><p>Please email the completed report by the deadline to:[email protected] NEQ 57, Issue 5 Page 3 of 4 Effective Date 15/02/17 Ref. SOP: 133/NEQ UK NEQAS for H&I – SCHEME 6 – HLA ANTIBODY DETECTION</p><p>Lab Number: Lab Name: </p><p>ADDITIONAL CDC RESULTS (Not Assessed – for participant information only) </p><p>Indicate the CDC percent panel reactive antibody (% PRA) for each sample. Enter NT if not tested. </p><p>T-Cell CDC B-Cell CDC PBL CDC</p><p>Panel Size: </p><p>%PRA %PRA %PRA Example NT 9 16</p><p>Comments</p><p>Please email the completed report by the deadline to:[email protected] NEQ 57, Issue 5 Page 4 of 4 Effective Date 15/02/17 Ref. SOP: 133/NEQ</p>